The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is projected to flourish at a CAGR of 6.8% from 2022 to 2031. As per the report published by TMR, the global IBD ...

Canada is among the countries with the highest prevalence of Crohn’s disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD), with about 270,000 Canadians living ...

You can develop IBD at any age, although the median age of onset is in the late 20s, adds Melmed. Today, there is no cure for Crohn’s disease or ulcerative colitis.

Some experts are now calling IBD an “immune-mediated” or “autoinflammatory” disease. Ulcerative colitis might be called an immune-mediated inflammatory disease with an autoimmune component.

Stelara was approved in 2016 to treat Crohn’s disease and in 2019 for ulcerative colitis. It was the first biologic medicine that targets interleukin (IL)-12 and IL-23.

World IBD Day takes place on Friday, May 19 to raise awareness of Crohn’s disease and ulcerative colitis, known as inflammatory bowel diseases (IBD). The day is coordinated by the European Federation ...

Ulcerative colitis is an inflammatory bowel disease that causes inflammation in parts of the digestive tract. Common signs of ulcerative colitis are diarrhea, belly pain, blood in the stool, and ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

According to the report’s forecasts, a full one per cent of the population — or 400,000 people — will have IBD by 2050. Scroll down to read the full Crohn’s and Colitis Canada report.

This report on the global IBD (Ulcerative Colitis & Crohn’s Disease) treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the ...